Challenges and perspectives of Chagas disease: a review

Pereira, Paulo Câmara Marques; Navarro, Elaine Cristina

doi:10.1186/1678-9199-19-34

Cited by 58 publications

(59 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…American trypanosomiasis, commonly known as Chagas disease (CD), is one of the most prevalent parasitic neglected tropical diseases (NTD) and a major cause of morbidity and mortality in many areas of Latin America according to the World Health Organization (WHO). Although the disease has its greatest impact on Latin America, its spread to the eastern hemisphere and first‐world countries has converted CD into a global problem, infecting more than 10 million people worldwide and more than 25 million are at risk of contracting CD …”

Section: Introductionmentioning

confidence: 99%

Synthesis and Biological in vitro and in vivo Evaluation of 2‐(5‐Nitroindazol‐1‐yl)ethylamines and Related Compounds as Potential Therapeutic Alternatives for Chagas Disease

et al. 2018

View full text Add to dashboard Cite

Chagas disease, a neglected tropical disease caused by infection with the protozoan parasite Trypanosoma cruzi, is a potentially life-threatening illness that affects 5-8 million people in Latin America, and more than 10 million people worldwide. It is characterized by an acute phase, which is partly resolved by the immune system, but then develops as a chronic disease without an effective treatment. There is an urgent need for new antiprotozoal agents, as the current standard therapeutic options based on benznidazole and nifurtimox are characterized by limited efficacy, toxicity, and frequent failures in treatment. In vitro and in vivo assays were used to identify some new low-cost 5-nitroindazoles as a potential antichagasic therapeutic alternative. Compound 16 (3-benzyloxy-5-nitro-1-vinyl-1H-indazole) showed improved efficiency and lower toxicity than benznidazole in both in vitro and in vivo experiments, and its trypanocidal activity seems to be related to its effect at the mitochondrial level. Therefore, compound 16 is a promising candidate for the development of a new anti-Chagas agent, and further preclinical evaluation should be considered.

show abstract

Section: Introductionmentioning

confidence: 99%

Synthesis and Biological in vitro and in vivo Evaluation of 2‐(5‐Nitroindazol‐1‐yl)ethylamines and Related Compounds as Potential Therapeutic Alternatives for Chagas Disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The study of sympatry in triatomines is an important parameter to evaluate the ability of T. cruzi to replicate and differentiate in the insect gut, because a good interaction between parasite and vector can accelerate the parasite diffusion in nature 40 . Results obtained in the present study demonstrate strong interaction between R. robustus and AM14 strain as well as between T. sordida and PR2256 strain, demonstrating that sympatry may favor both infectivity and transmission capacity of the parasite by the insect vector, because in the groups of allopatric species, which are geographically isolated (R. robustus and PR2256 strain and T. sordida and AM14 strain), the infection was less efficient.…”

Section: Dworak Es Et Al -Interaction Of T Cruzi With Triatominementioning

confidence: 99%

Sympatry influence in the interaction of Trypanosoma cruzi with triatomine

Dworak

Araújo

Gomes

et al. 2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Trypanosoma cruzi, the etiologic agent of Chagas disease, is widely distributed in nature, circulating between triatomine bugs and sylvatic mammals, and has large genetic diversity. Both the vector species and the genetic lineages of T. cruzi present a varied geographical distribution. This study aimed to verify the influence of sympatry in the interaction of T. cruzi with triatomines. Methods: The behavior of the strains PR2256 (T. cruzi II) and AM14 (T. cruzi IV) was studied in Triatoma sordida (TS) and Rhodnius robustus (RR). Eleven fifth-stage nymphs were fed by artificial xenodiagnosis with 5.6 × 10 3 blood trypomastigotes/0.1mL of each T. cruzi strain. Every 20 days, their excreta were examined for up to 100 days, and every 30 days, the intestinal content was examined for up to 120 days, by parasitological (fresh examination and differential count with Giemsa-stained smears) and molecular (PCR) methods. Rates of infectivity, metacyclogenesis and mortality, and mean number of parasites per insect and of excreted parasites were determined. Results: Sympatric groups RR+AM14 and TS+PR2256 showed higher values of the four parameters, except for mortality rate, which was higher (27.3%) in the TS+AM14 group. General infectivity was 72.7%, which was mainly proven by PCR, showing the following decreasing order: RR+AM14 (100%), TS+PR2256 (81.8%), RR+PR2256 (72.7%) and TS+AM14 (36.4%). Conclusions: Our working hypothesis was confirmed once higher infectivity and vector capacity (flagellate production and elimination of infective metacyclic forms) were recorded in the groups that contained sympatric T. cruzi lineages and triatomine species.

show abstract

“…In 2008 alone, more than 10,000 deaths from Chagas disease were reported [62]. Since the 1990s, multinational initiatives have led to significant reductions in the number of acute cases of Chagas disease and in the presence of domestic triatomine vectors in many endemic regions of Latin America [1].…”

Section: Reviewmentioning

confidence: 99%

The history of Chagas disease

Steverding

2014

Parasites & Vectors

118

View full text Add to dashboard Cite

The ancestor of Trypanosome cruzi was probably introduced to South American via bats approximately 7-10 million years ago. When the first humans arrived in the New World, a sylvatic cycle of Chagas disease was then already well established. Paleoparasitological data suggests that human American trypanosomiasis originated in the Andean area when people founded the first settlements in the coastal region of the Atacama Desert. Identification of T. cruzi as the etiological agent and triatome bugs as the transmission vector of Chagas disease occurred within a few years at the beginning of the 20th century. History also teaches us that human activity leading to environmental changes, in particular deforestation, is the main cause for the spread of Chagas disease. Recently, migration of T. cruzi-infected patients has led to a distribution of Chagas disease from Latin America to non-endemic countries in Europe, North America and western Pacific region.

show abstract

Challenges and perspectives of Chagas disease: a review

Cited by 58 publications

References 54 publications

Synthesis and Biological in vitro and in vivo Evaluation of 2‐(5‐Nitroindazol‐1‐yl)ethylamines and Related Compounds as Potential Therapeutic Alternatives for Chagas Disease

Synthesis and Biological in vitro and in vivo Evaluation of 2‐(5‐Nitroindazol‐1‐yl)ethylamines and Related Compounds as Potential Therapeutic Alternatives for Chagas Disease

Sympatry influence in the interaction of Trypanosoma cruzi with triatomine

The history of Chagas disease

Contact Info

Product

Resources

About